Stockreport

Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient [Yahoo! Finance]

Atossa Therapeutics, Inc.  (ATOS) 
Last atossa therapeutics, inc. earnings: 11/13 04:10 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.atossagenetics.com
PDF pre-menopausal, Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-), breast cancer patient who received neoadjuvant and adjuvant [Read more]